Want to join the conversation?
$AGN said FDA approved its supplemental New Drug Application (sNDA) to update label for AVYCAZ (ceftazidime and avibactam) with clinical data from Phase 3 trial evaluating safety and efficacy of AVYCAZ, in combination with metronidazole, for treatment of complicated intra-abdominal infections (cIAI) caused by designated susceptible microorganisms.
Keep your eyes on $FLXN. This one could ascend rapidly. Great time to buy your favourite bio stocks. Make more $$$
$CRM on the pop today.. big bubble.
Slumping and down the drain... $HDSN. Flush out your holdings !
$KITE I am loving this one... really flying like a kite today :-)